Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
1.440
+0.110 (8.27%)
At close: Dec 11, 2025, 4:00 PM EST
1.430
-0.010 (-0.69%)
After-hours: Dec 11, 2025, 5:59 PM EST
Jaguar Health Revenue
Jaguar Health had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -0.80%. This brings the company's revenue in the last twelve months to $11.79M, down -34.31% year-over-year. In the year 2024, Jaguar Health had annual revenue of $11.69M with 19.75% growth.
Revenue (ttm)
$11.79M
Revenue Growth
-34.31%
P/S Ratio
0.14
Revenue / Employee
$240,510
Employees
49
Market Cap
5.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
JAGX News
- 1 day ago - FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 3 days ago - Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - Accesswire
- 9 days ago - Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study - Accesswire
- 17 days ago - Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - Accesswire
- 21 days ago - In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial - Accesswire
- 24 days ago - Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 24 days ago - Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Accesswire
- 27 days ago - Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Accesswire